President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and ...

Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of ...

A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...

The company plans to create a new category of cellular medicines offering functional cures for metabolic and endocrine ...

President-elect Donald Trump threatened Tuesday to place new tariffs on imports from Denmark unless the country gives up control of Greenland, news that dented the stocks of some of Denmark's most ...

British fund manager Terry Smith has sold his stake in Diageo Plc, citing concerns about the management of the drinks company and its vulnerability to soaring demand for weight-loss drugs.

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Medicare drug plans can now cover Eli Lilly & Co.'s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that's expected to prove a big boost for the drug company.

Brown-Forman's stock is a compelling investment with stable revenue and profit margins. Learn why BF.B is a Buy.

The fund benefits from Baillie Gifford’s bold attitude but a portfolio shake-up has made it much more appealing to investors ...

Greenland may become independent if its residents want, but is unlikely to become a US state, Denmark’s foreign minister said ...

Novo Nordisk A/S (NVO) stock saw a modest uptick, ending the day at $85.64 which represents a slight increase of $2.30 or 2.76% from the prior close of $83.34. The stock opened at $85.51 and touched a ...